Phadia Analyzer 250

The Defense Health Agency awarded a sole-source contract to Phadia US Inc. for a Phadia Analyzer 250 system with associated supplies and reagents on July 17, 2026, with a total contract value of $1,297,265.70.

The contract covers a base period plus four option years under firm fixed-price terms. Performance is at Tripler Army Medical Center in Hawaii. The award was made without a set-aside; the contracting activity (Defense Health Agency Contracting Activity, Healthcare Contracting Division-West) executed the procurement on behalf of the Navy. Phadia was determined to be the sole source capable of meeting TAMC's Core Laboratory requirements for automated allergy and autoimmune testing. The Phadia 250 is the only FDA-cleared platform capable of fully automated allergy and autoimmune testing on a single consolidated system, and Phadia holds exclusive manufacturing rights to specialized reagents for testing specific allergens including tilapia, sunflower seeds, bayberry, house dust, and peanut components. Market research conducted January through April 2026 and a SAM.gov notice of intent posted April 10–25, 2026 confirmed no alternative sources exist. Without this procurement, TAMC would be forced to cease in-house allergy testing, resulting in substantial patient care delays and an estimated 35 percent increase in laboratory operational costs.